Phase 1 trial of valemetostat and darolutamide in mCRPC

2025-522512-16-00 Protocol DS3201-343 Human pharmacology (Phase I) - Other Authorised, recruiting

Start 23 Apr 2026 · Status Authorised, recruiting · 3 EU/EEA countries · 7 sites · Protocol DS3201-343

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruiting
Participants planned 60
Countries 3
Sites 7

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Key facts

Sponsor
Daiichi Sankyo Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
23 Apr 2026 → ongoing
Decision date (initial)
2026-03-18
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic Castration Resistant Prostate Cancer (mCRPC)

VersionLevelCodeTermSystem organ class
28.0 SOC 10029104 Neoplasms benign malignant and unspecified (incl cysts and polyps) 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Daiichi Sankyo Inc.

Sponsor organisation
Daiichi Sankyo Inc.
Address
211 Mount Airy Road
City
Basking Ridge
Postcode
07920-2311
Country
United States

Scientific contact point

Organisation
Daiichi Sankyo Inc.
Contact name
Clinical Trial Office

Public contact point

Organisation
Daiichi Sankyo Inc.
Contact name
Clinical Trial Office

Locations

3 EU/EEA countries · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 4 2
Ireland Authorised, recruiting 2 1
Spain Authorised, recruiting 7 4
Rest of world
Japan, United States, Australia, China
47

Investigational sites

France

2 sites · Ongoing, recruiting
Centre Leon Berard
Oncology, 28 Rue Laennec, 69008, Lyon
Centre Oscar Lambret
Oncology, 3 Rue Frederic Combemale, 59000, Lille

Ireland

1 site · Authorised, recruiting
Mater Misericordiae University Hospital
Oncology, Eccles Street, D07 R2WY, Dublin 7

Spain

4 sites · Authorised, recruiting
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Quironsalud Barcelona
Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital San Pedro
Oncology, Calle Piqueras 98, 26006, Logrono

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2026-05-26 2026-05-26
Ireland 2026-04-23
Spain 2026-05-15

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-11-05 Ireland Acceptable
2026-03-16
2026-03-18
2 SUBSTANTIAL MODIFICATION SM-1 2026-03-27 Acceptable 2026-05-04